Bell’s palsy following COVID-19 vaccination

@article{Colella2021BellsPF,
  title={Bell’s palsy following COVID-19 vaccination},
  author={Giuseppe Colella and Massimiliano Orlandi and Nicola Cirillo},
  journal={Journal of Neurology},
  year={2021},
  pages={1 - 3}
}
Currently two Coronavirus Disease 2019 (COVID-19) vaccines have been granted emergency use and marketing authorization by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1, 2]. Initial efficacy and safety data for both BNT162b2 (PfizerBioNTech) and mRNA-1273 (Moderna) vaccines have been published [3, 4]. To the best of our knowledge, there is no mention of facial paralysis in the article describing safety and efficacy of the BNT162b2 vaccine [3], however, four… Expand

Figures from this paper

Bell’s palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report
TLDR
In a young and healthy patient, a previous facial palsy during pregnancy and the presence of VZV-IgG antibodies could be associated with an increased predisposition to facial nerve palsy, but evidence of a temporal association between the vaccine administration and the facial nerves palsy is clear: Bell’s palsy appeared 2 days after the administration of the mRNA COVID-19 vaccine. Expand
Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The case of a 36-year-old previously healthy patient who developed symptoms of Bell’s palsy along with left-arm numbness, tingling, and subjective weakness masquerading as a subacute stroke after receiving the second dose of the mRNA-1273 vaccine is reported. Expand
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
TLDR
Although it is found that there is an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test. Expand
COVID-19 mRNA vaccination leading to CNS inflammation: a case series
TLDR
Seven patients who received the Moderna or Pfizer SARS-CoV-2 mRNA vaccines developed neurologic symptoms and MRI findings consistent with active CNS demyelination of the optic nerve, brain, and/or spinal cord within one to 21 days of either the first or second vaccine dose. Expand
Ocular Adverse Events After COVID-19 Vaccination
TLDR
It is hypothesize that the human body’s immune response to COVID-19 vaccinations may be involved in the pathogenesis of the ocular adverse effects post-CO VID-19 vaccination. Expand
Spectrum of neurological complications following COVID-19 vaccination
  • Ravindra Kumar Garg, V. Paliwal
  • Medicine
  • Neurological Sciences
  • 2021
TLDR
Considering the enormity of recent COVID-19-vaccinated population, the number of serious neurological events is miniscule and large collaborative prospective studies are needed to prove or disprove causal association between vaccine and neurological adverse events occurring vaccination. Expand
Bell’s palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell’s palsy: A case report
  • Binyan Yu, L. Cen, Ting Chen, Tian-Hong Yang
  • Medicine
  • World journal of clinical cases
  • 2021
TLDR
A history of Bell's palsy, rapid increase of immunoglobulin M and immunoglobin G-specific antibodies to severe acute respiratory syndrome coronavirus 2 may be risk factors for Bell’s palsy after inactivated COVID-19 vaccination. Expand
Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence?
TLDR
The lesions seen on magnetic resonance imaging (MRI) of three patients who developed neurological symptoms after receiving the ChAdOX1 nCoV-19 vaccine (Oxford/AstraZeneca) are described. Expand
Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study.
TLDR
No association was found between recent vaccination with the BNT162b2 vaccine and risk of facial nerve palsy and analysis of the number of admissions during the study period revealed a relatively stable trend. Expand
Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase
TLDR
Findings might support clinicians in decision-making for patients potentially at risk for developing an acute inflammatory neuropathy with COVID-19 vaccines and across potential risk groups by sex and age. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 16 REFERENCES
Reported orofacial adverse effects of COVID‐19 vaccines: The knowns and the unknowns
  • N. Cirillo
  • Medicine
  • Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • 2021
TLDR
There are inconsistencies in the description of adverse effects presenting in the orofacial region of the COVID‐19 vaccines BNT162b2 and mRNA‐1273, and it is believed that awareness of these o rofacial manifestations will improve recognition, management and reporting of vaccine‐related adverse effects. Expand
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines. Expand
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified. Expand
Clinical Practice Guideline: Bell’s Palsy
Program Description: This miniseminar will consist of a lively panel discussion on the evidence-based recommendations for the treatment and management of Bell’s palsy as outlined in the recentlyExpand
EPAR product information characteristics
  • https ://www.ema.europ a.eu/en/docum Fig. 1 Clinical photograph of our 37-year-old patient with left-sided facial droop 3591 Journal of Neurology
  • 2021
  • Otolaryngol Head Neck Surg
  • 2020
Clinical Trial Group et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
  • N Engl J Med
  • 2020
Comirnaty: EPAR product information characteristics
  • European Medicine Agency
  • 2020
    C4591001 Clinical Trial Group et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
    • N Engl J Med
    ...
    1
    2
    ...